AEs With BCL-2i/PI3Ki

CE / CME

Multidisciplinary Perspectives on Managing Adverse Events With BCL-2 and PI3K Inhibitors in CLL

Pharmacists: 0.50 contact hour (0.05 CEUs)

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Nurses: 0.50 Nursing contact hour

Released: May 19, 2022

Expiration: May 18, 2023

Nichole Fisher
Nichole Fisher, RN, BSN
Nicole Lamanna
Nicole Lamanna, MD
Anthony J Perissinotti
Anthony J Perissinotti, PharmD, BCOP

Activity

Progress
1
Course Completed
References

  1. Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380:2225-2236.
  2. Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378:1107-1120.
  3. Anderson MA, Huang D, Roberts A. Targeting BCL2 for the treatment of lymphoid malignancies. Semin Hematol. 2014;51:219-227.
  4. Venetoclax prescribing information. North Chicago, IL: AbbVie Inc.; 2021.
  5. Fischer K, Al-Sawaf O, Hallek M. Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2020;2020:357-362.
  6. Idelalisib prescribing information. Foster City, CA: Gilead Sciences, Inc.; 2022.
  7. Duvelisib prescribing information. Las Vegas, NV: Secura Bio, Inc.; 2021.
  8. Copanlisib prescribing information. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.; 2017.
  9. Umbralisib prescribing information. Edison, NJ: TG Therapeutics, Inc.; 2020.
  10. Hanlon A, Brander DM. Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors. Hematology Am Soc Hematol Educ Program. 2020;2020:346-356.
  11. Gribben JG, Jurczak W, Jacobs R, et al. Umbralisib plus ublituximab (U2) is superior to obinutuzumab plus chlorambucil (O+Chl) in patients with treatment naïve (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Results from the phase 3 UNITY-CLL study. Presented at: 2020 American Society of Hematology Annual Meeting; December 5-8, 2020. Abstract 543.